Atorvastatin interactions
Searched over 200M research papers for "atorvastatin interactions"
Summary
10 papers analyzed
Some studies suggest atorvastatin has no significant interaction with fenofibrate or ximelagatran, while other studies indicate interactions with cyclosporine A, omega-3 fatty acids, and dronedarone, and variability in pharmacokinetics in aging people with HIV.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Atorvastatin Interactions: A Comprehensive Overview
Introduction to Atorvastatin Interactions
Atorvastatin, a widely prescribed statin, is known for its efficacy in lowering cholesterol levels. However, its interactions with other drugs can significantly impact its pharmacokinetics and pharmacodynamics. This article synthesizes current research on atorvastatin interactions, focusing on its co-administration with various drugs and the resulting clinical implications.
Atorvastatin and Fenofibrate: No Significant Interaction
A study investigating the pharmacokinetic interaction between atorvastatin and fenofibrate found no significant clinical-pharmacokinetic interaction between the two drugs. The study involved healthy volunteers and measured parameters such as the area under the concentration-time curve (AUC) and maximum plasma drug concentration (Cmax). The results indicated that the combination of atorvastatin and fenofibrate did not alter the pharmacokinetic profile of atorvastatin significantly.
Atorvastatin and Cyclosporin A: Variable Interaction
Research on renal transplant recipients treated with cyclosporin A (CsA) revealed variable interactions with atorvastatin. While cerivastatin did not affect CsA levels, atorvastatin increased CsA levels in some patients. This suggests a need for careful monitoring of CsA levels when co-administered with atorvastatin to avoid potential toxicity. Another study confirmed this bilateral pharmacokinetic interaction, emphasizing the importance of dose adjustments and monitoring in clinical settings.
Atorvastatin and Bovine Serum Albumin: Binding Dynamics
The interaction of atorvastatin with bovine serum albumin (BSA) was studied using spectroscopic methods and molecular docking. The findings showed that atorvastatin binds to BSA through van der Waals forces and hydrogen bonding, with a binding constant indicating a strong interaction. This binding affects the transport and storage of atorvastatin in the body, potentially influencing its pharmacokinetics.
Atorvastatin and Omega-3 Fatty Acids: Pharmacokinetic Interaction
A phase 1 trial evaluated the interaction between atorvastatin and omega-3 fatty acids. The study found that co-administration altered the pharmacokinetics of both atorvastatin and its metabolites, suggesting a significant interaction. This interaction necessitates careful consideration when prescribing these agents together to ensure therapeutic efficacy and safety.
Atorvastatin and Antiretrovirals: Impact on Pharmacokinetics
In people living with HIV, atorvastatin's pharmacokinetics were significantly affected by co-administration with antiretrovirals (ARVs). Boosted ARVs decreased atorvastatin clearance and slowed metabolite formation, leading to increased atorvastatin exposure. This interaction highlights the need for dose adjustments and close monitoring in this patient population.
Atorvastatin and Dronedarone: CYP3A4 Mediated Interaction
The interaction between atorvastatin and dronedarone, mediated by CYP3A4, was studied using molecular dynamics simulations. Atorvastatin and its lactone form inhibited dronedarone binding and metabolism, with the lactone form being the primary modulator. This interaction underscores the complexity of atorvastatin's metabolism and the potential for significant drug-drug interactions.
Atorvastatin and Ximelagatran: No Significant Interaction
A study on the interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran found no significant pharmacokinetic or pharmacodynamic interaction. This suggests that atorvastatin can be safely co-administered with ximelagatran without altering its therapeutic effects.
Conclusion
Atorvastatin interacts with various drugs through different mechanisms, primarily involving metabolic pathways mediated by CYP3A4. While some interactions necessitate dose adjustments and careful monitoring, others do not significantly impact atorvastatin's pharmacokinetics. Understanding these interactions is crucial for optimizing therapeutic outcomes and ensuring patient safety.
Sources and full results
Most relevant research papers on this topic
